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Aldo-keto reductases are biomarkers of
NRF2 activity and are co-ordinately
overexpressed in non-small cell lung cancer
A Kenneth MacLeod1, Lourdes Acosta-Jimenez1, Philip J Coates1,4, Michael McMahon1, Frank A Carey2,
Tadashi Honda3, Colin J Henderson1 and C Roland Wolf*,1
1Division of Cancer Research, School of Medicine, University of Dundee, Ninewells Hospital, Dundee DD1 9SY, UK; 2Department
of Pathology and Neuroscience, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK and 3Department of Chemistry and
Institute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, NY 11794-3400, USA
Background: Although the nuclear factor-erythroid 2-related factor 2 (NRF2) pathway is one of the most frequently dysregulated
in cancer, it is not clear whether mutational status is a good predictor of NRF2 activity. Here we utilise four members of the aldo-
keto reductase (AKR) superfamily as biomarkers to address this question.
Methods: Twenty-three cell lines of diverse origin and NRF2-pathway mutational status were used to determine the relationship
between AKR expression and NRF2 activity. AKR expression was evaluated in lung cancer biopsies and Cancer Genome Atlas
(TCGA) and Oncomine data sets.
Results: AKRs were expressed at a high basal level in cell lines carrying mutations in the NRF2 pathway. In non-mutant cell lines,
co-ordinate induction of AKRs was consistently observed following activation of NRF2. Immunohistochemical analysis of lung
tumour biopsies and interrogation of TCGA data revealed that AKRs are enriched in both squamous cell carcinomas (SCCs) and
adenocarcinomas that contain somatic alterations in the NRF2 pathway but, in the case of SCC, AKRs were also enriched in most
other tumours.
Conclusions: An AKR biomarker panel can be used to determine NRF2 status in tumours. Hyperactivation of the NRF2 pathway is
far more prevalent in lung SCC than previously predicted by genomic analyses.
NRF2 is a cap‘n’collar (CNC) basic-region leucine zipper (bZIP)
transcription factor that regulates a diverse battery of cytoprotec-
tive genes that collectively allow cells to survive transient periods of
exposure to electrophilic, oxidative and inflammatory stress (Itoh
et al, 1997; Hayes et al, 2010). The stability, abundance and activity
of NRF2 is primarily governed by kelch-like ECH-associated
protein 1 (KEAP1), a homodimeric substrate adaptor that recruits
the factor to the Cullin 3/Ring-box 1 (CUL3/RBX1) E3 ubiquitin
ligase holoenzyme, targeting it for ubiquitylation and subsequent
proteasomal degradation (Itoh et al, 1999; McMahon et al, 2003).
This targeting is inhibited by toxic electrophiles, such as lipid
peroxidation products or the reactive metabolites of chemicals or
therapeutic drugs, which directly modify reactive cysteine residues
on KEAP1, leading to nuclear accumulation of NRF2 and increased
transcription of cytoprotective genes (Dinkova-Kostova et al,
2002).
The increased capacity to inactivate genotoxic electrophiles
conferred by activation of NRF2 can reduce the rate at which
normal cells accumulate mutations, and can thereby inhibit
chemically mediated carcinogenesis in animal models. Accord-
ingly, Nrf2-null mice are more susceptible to this process (Ramos-
Gomez et al, 2001). However, following tumorigenesis, NRF2 may
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have a role in the malignant progression of lung adenoma to
adenocarcinoma as the incidence and malignant characteristics of
tumours in wild-type animals are greater than those in Nrf2-
knockout animals (Satoh et al, 2013). Generally, once a cancer has
emerged, increased NRF2 activity is thought to promote cell
survival and proliferation under conditions of environmental stress
or in the face of chemotherapy (Hayes and McMahon, 2009).
Consistent with this, genetic, epigenetic and signalling changes in
tumours that exacerbate NRF2 activity have been associated with
poor patient outcome (Shibata et al, 2008b). For this reason, NRF2
inhibition has emerged as a potential chemotherapeutic strategy.
Research into NRF2 has been impeded by the lack of sufficiently
specific and sensitive antibodies. Its abundance is often, therefore,
inferred from target gene/protein expression levels. This target
gene battery is well defined in mouse, but is not so thoroughly
characterised in man. Microarray and ChIP-Seq analyses of mouse
cells have established that the CNC/bZIP factor is involved in the
transcriptional regulation of several hundred genes (Thimmulappa
et al, 2002; Malhotra et al, 2010). In human cell lines, a number of
studies have identified the transcriptomic and, in some cases,
proteomic changes that arise upon chemical or genetic perturba-
tion of NRF2 signalling (MacLeod et al, 2009; Agyeman et al,
2012). Much of the NRF2 target gene battery is conserved between
mouse, rat and man. Common targets include genes involved in
antioxidant processes, NADPH generation, metal binding and the
stress response (Hayes et al, 2010). There is divergence, however, in
the drug metabolism enzyme targets of NRF2. In mouse,
glutathione S-transferases (GSTs) predominate, while the aldo-
keto reductases (AKRs) are more conspicuous when human cells
are examined. AKR1B10, AKR1C1, AKR1C2 and AKR1C3
constitute some of the most inducible targets of NRF2 in human
systems, both normal and tumour-derived (Lou et al, 2006;
MacLeod et al, 2009; Agyeman et al, 2012; Jung et al, 2013). The
DNA motif bound by NRF2, the antioxidant response element
(ARE), has been identified in the promoters of AKR1B10, AKR1C1
and AKR1C2 (Lou et al, 2006; Nishinaka et al, 2011).
In order to examine whether the ability of NRF2 to drive AKR
gene transcription is ubiquitous in human cell types of different
origin, we have measured the expression of mRNA and protein for
these targets in a panel of cultured cell lines (mostly tumour-
derived) in both basal and induced states. We show that AKR
expression is related to the status of the NRF2/KEAP1 pathway
and can be used as a readout for the activation or inhibition of
NRF2. Through immunohistochemical analysis of lung tumour
biopsies and interrogation of data from The Cancer Genome Atlas
(TCGA), we have found that AKRs are enriched in both SCC and
AC that contain somatic alterations in the NRF2 pathway but, in
the case of SCC, AKR enrichment also occurs in cells not carrying
NRF2 or KEAP1 mutation. These data indicate that NRF2 is
frequently constitutively activated by alternative mechanisms in
this cancer type and, therefore, that genetic analyses alone cannot
determine the contribution of NRF2 to the tumour phenotype.
MATERIALS AND METHODS
Cell lines. A panel of cell lines containing either wild type or
mutant forms of NRF2 or KEAP1, as confirmed by the Wellcome
Trust Sanger Institute COSMIC database, was assembled. The
origin, authentication and culture conditions of these cell lines are
described in detail in Supplementary Materials and Methods.
Characteristics of the mutant cell lines are detailed in
Supplementary Table 1. All lines were free of mycoplasma
contamination, as verified using the MycoAlert Mycoplasma
detection kit (Lonza, Basel, Switzerland). In contrast to previous
reports (Singh et al, 2006), the Wellcome Trust Sanger Institute
COSMIC database states that the H23 cell line contains a
homozygous mutation in KEAP1 (579G4C, Q193H), while
neither H1395 nor H1993 contain the reported heterozygous
mutation (both 1048G4A, G350S). Our sequencing of these cell
lines agreed with the Sanger database entries in each case
(Supplementary Figure 1).
Cell treatments, sample preparation and ELISA. Sulforaphane
(SFN) was purchased from LKT laboratories (St Paul, MN, USA).
(±)-(4aa, 8aa, 10ab)-1, 2, 4a, 6, 8a, 9, 10, 10a-octahydro-8a-
ethynyl-1,1,4a-trimethyl-2,6-dioxophenanthrene-3,7-dicarbonitrile
(TBE-31) was synthesised as described previously (Honda et al,
2007; Saito et al, 2013). Cells were treated with 5 mmol l 1 SFN or
0.2 mmol l 1 TBE-31 in 0.1% acetonitrile vehicle on reaching
50–70% confluency, and protein or cDNA samples prepared 24 h
later. For knockdown experiments, A549 and H838 cells were
reverse-transfected with ON-TARGETplus NRF2 (L-003755-00)
and non-targeting (D-001810-10-05) siRNA SMARTpools, each
containing four siRNAs (Dharmacon, Thermo Fisher Scientific,
Waltham, MA, USA), at a final concentration of 10 nmol l 1, in
complex with Lipofectamine RNAiMAX (Life Technologies,
Carlsbad, CA, USA). Cells were lysed for analysis at the timepoints
indicated. For fractionation of nuclear and cytoplasmic compart-
ments, cells were processed using the NE-PER Nuclear and
Cytoplasmic Extraction kit (Thermo Fisher Scientific). ELISAs
were carried out by the In-Cell colorimetric method (Thermo
Fisher Scientific) and statistical significance evaluated by unpaired
t-test: *Pp0.05, **Pp0.01, ***Pp0.001.
Antibodies and western blotting. Rabbit polyclonal anti-
AKR1B10, anti-AKR1C1, anti-NQO1, anti-KEAP1 and anti-NRF2
were kindly provided by Professor John Hayes, University of Dundee.
Mouse polyclonal anti-AKR1C1 (ab72576), mouse monoclonal anti-
GAPDH (ab8245), mouse monoclonal anti-TBP (ab51841) and rabbit
monoclonal anti-LDH (ab52488) were purchased from Abcam
(Cambridge, UK). Mouse monoclonal anti-AKR1C3 was a kind gift
from Professor Trevor Penning, University of Pennsylvania, PA, USA.
SDS–PAGE and western blotting were carried out as described
previously (MacLeod et al, 2009).
Measurement of mRNA levels. mRNA analysis was carried out in
96-well plate format using Applied Biosystems’ TaqMan Gene
Expression Cells-to-CT kit (Life Technologies) according to the
manufacturer’s instructions. All real-time PCR primer and probe
sets were purchased from Applied Biosystems (Foster City, CA,
USA); AKR1B10 (Hs00252524_m1), AKR1C1/2 (Hs00413886
_m1), AKR1C3 (Hs00366267_m1), NRF2 (Hs00975960_m1),
Actin B internal standard (4352935E). Assays were performed in
triplicate and fold changes calculated using the 2( dd C(T))
method. Fold changes for inducer-treated cells were calculated
relative to vehicle-treated cells and the heatmap generated using
ggplot2 in R. Statistical significance was evaluated using an
unpaired t-test. For Figures 3B and C: *Pp0.05, **Pp0.01,
***Pp0.001. For Supplementary Table 2, FDR (Q) was set to 1%
and significant differences are denoted ‘*’.
TCGA data retrieval and analysis. All gene expression and
mutation data for AC and SCC were derived from publicly
available TCGA datasets (15 July 2015, https://tcga-data.nci.nih.-
gov/tcga/). For AC, analyses were performed on the ‘TCGA,
Nature 2014’ data set. For SCC, analyses were performed on the
‘TCGA Provisional’ data set (mutation information from samples
shared with the ‘TCGA, Nature 2012’ data set). Normalised level 3
RNA-seq gene expression values, as determined using the RNA-
Seq by Expectation Maximisation (RSEM) algorithm, were
retrieved using the TCGA-Assembler package in R and RStudio
(Zhu et al, 2014). Mutation data for NRF2 and KEAP1 were
retrieved using the cBioPortal web application programming
interface (www.cbioportal.org). For the comparison of wild type
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with mutant non-small cell lung cancer (NSCLC), we analysed 230
cases of AC (179 wild type, 51 mutant) and 178 cases of SCC (120
wild type, 58 mutant). For the comparison of tumour to matched
normal tissue we analysed data for 45 tumour/normal (35 wild
type, 10 mutant) paired AC and 16 tumour/normal (11 wild type, 5
mutant) paired SCC samples. All data processing and statistical
analyses were carried out in R using packages cgdsr, plyr and
ggplot2. Association was evaluated by unpaired and paired
Wilcoxon ranked test for wild-type vs mutant values (Figure 4)
and matched normal vs tumour values (Figure 5), respectively.
RESULTS
NRF2 or KEAP1 mutation leads to a high basal level of AKR1B,
AKR1C1/2 and AKR1C3 expression. Whole-cell lysates were
prepared from a panel of cell lines, some of which carry mutations
in NRF2 or KEAP1, and AKR protein expression measured by
western blotting (Figure 1). The rabbit antibody raised against
AKR1B10 (36.02 kDa) also reacts with AKR1B1 (35.85 kDa).
Similarly, as AKR1C1 (36.79 kDa) and AKR1C2 (36.74 kDa)
proteins are 98% identical, it is likely that the mouse polyclonal
antibody used to detect AKR1C1 cross-reacts with AKR1C2. The
mouse monoclonal antibody used to detect AKR1C3 is highly
specific; cross-reactivity with recombinant forms of human
AKR1A, AKR1B, AKR1C and AKR1D superfamily members was
not observed (data not shown).
AKR1B, AKR1C1/2 and AKR1C3 were all expressed constitu-
tively at the highest levels in A549, H460 (both of which are
homozygous for mutations in KEAP1) and HO1-u-1 (heterozygous
for NRF2 mutation, Figure 1). In addition, AKR1C1/2 was also
highly expressed in LK-2 cells (homozygous for NRF2 mutation),
while AKR1C3 was expressed at low, but detectable, levels in H838
(homozygous for KEAP1 mutation), 5637 and MDA-MB-231
(KEAP1 and NRF2 wild type) cells (Figure 1). It should be noted
that none of the cell lines possess mutant CUL3, with the exception
of H460 (1299C4T, T410I), which also carries mutant KEAP1
(Supplementary Table 1).
AKR1B, AKR1C1/2 and AKR1C3 are inducible in cell lines with
functional, but not mutated, KEAP1/NRF2. Cell lines were
treated for 24 h with two NRF2 inducers; SFN, an isothiocyanate
and a widely used activator of NRF2, and TBE-31, a highly potent
tricyclic-bis-enone inducer (Honda et al, 2007; Liby et al, 2008).
Remarkably, Taqman analysis of RNA indicated that SFN and
TBE-31 induced AKR1B10, AKR1C1/2 and AKR1C3 mRNA in
almost all tumour cell lines with wild-type KEAP1 and NRF2,
independent of the tissue or origin (Figure 2, fold change values are
provided in Supplementary Table 2). At the concentrations tested,
fold induction in response to TBE-31 was generally much greater
than in response to SFN. The presence of two cyano enone
moieties within TBE-31 have previously been shown to underpin
this high relative potency. With the exception of H23, AKRs were
not inducible in cell lines with biallelic mutations in KEAP1 or NRF2.
In one cell line carrying heterozygous NRF2 mutation, EBC-1, AKR
mRNAs could still be modestly upregulated in response to inducer
treatment.
In many of the cell lines homozygous for wild-type KEAP1 and
NRF2, the induction of AKR mRNA was paralleled by an increase
in protein (Figure 3A, summarised in Supplementary Table 3). In
some cell lines, all targets were induced (for example, OVC433,
A431, HaCaT and MCF-7 cells) while, in others the induction was
much less marked. The western blots shown in Figure 3A were
exposed for varying lengths of time in order to optimise
chemiluminescent signal intensity to determine AKR induction
on a cell line basis. The data should therefore not be compared
directly with Figure 1. In many cases, AKR expression was close to
or below the limit of detection with the blotting protocol applied,
preventing a full comparison with the mRNA data. No induction
of AKR proteins was detected in any of the KEAP1/NRF2
mutant cell lines, with the exception of AKR1C1/2 in HO1-u-1
cells. Western blotting for NAD(P)H dehydrogenase, quinone 1
(NQO1), the protein most commonly used as a proxy measure of
NRF2 activity, showed that it was constitutively expressed in
almost all of the cell lines, being undetectable in only AD293 and
MDA-MB-231. NQO1 was inducible in many of the lines
homozygous for wild-type KEAP1 and NRF2, but the fold changes
were less than those of the AKRs. NQO1 was not inducible in the
mutant cell lines.
Knockdown of NRF2 in KEAP1 homozygous mutant cells leads
to decreases in AKR1C1 expression. The A549 and H838 cell
lines, which lack functional KEAP1 and hence exhibit elevated
NRF2 activity (Singh et al, 2006), were transfected with either non-
targeting siRNA (siNT), or siRNA against NRF2 (siNRF2). In both
cell lines, NRF2 knockdown reduced the mRNA level to between
20 and 50% of control level (Figure 3B), with a concomitant
decrease in the level of AKR1C1/2 mRNA to B5–20% of control,
after 48 h (Figure 3C). Protein levels for both NRF2 and AKR1C1/2
were decreased in A549 cells, and this effect was maintained up to
120 h (Figure 3D). AKR1C1/2 depletion after 120 h was also
observed by the In-Cell ELISA method, using mouse polyclonal
anti-AKR1C1, in both A559 and H838 cells (Figure 3E). The
proportion of decrease in AKR1C1/2 expression is similar to
that of other NRF2 targets, as described in previous studies
(Singh et al, 2006, 2008).
AKR1B, AKR1C1/2 and AKR1C3 are co-ordinately upregulated
in the majority of lung SCC and in the minority of lung
AC. Rabbit polyclonal anti-AKR1B10 and anti-AKR1C1 and
mouse monoclonal anti-AKR1C3 were used for immunohisto-
chemistry. All three of these primary antibody preparations give
single bands on western blot of whole-cell lysate protein samples
from A549 cells, indicating their specificity (Supplementary
Figure 2). We initially determined whether the antibodies were
suitable for immunohistochemistry by staining FFPE preparations
of cultured cell lines; the MCF-7-derived AREc32 cell line, in which
NRF2 activity is inducible, and the A549 cell line, in which NRF2
activity is high due to a homozygous inactivating mutation in
KEAP1 (Singh et al, 2006). The anticipated pattern of expression
was observed, wherein AREc32 cells show minimal staining that is
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Figure 1. AKR1B, AKR1C1/2 and AKR1C3 are expressed at high levels
in cell lines carrying mutant KEAP1 or NRF2. Western blotting of
whole-cell lysates for AKR1B, AKR1C1/2 and AKR1C3 was carried out
as described in Materials and Methods. Samples were prepared and
analysed in parallel and uniformity of sample loading on the gels was
verified by Coomassie blue staining (data not shown). *NRF2 and
KEAP1 mutational status in AD293 and HaCaT cell lines unknown.
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increased following treatment with 5mM SFN for 24 h, and A549
cells show the strongest staining, reflecting their KEAP1 mutant
status (Supplementary Figure 3).
Fifteen FFPE samples of NSCLC were classified by conventional
histological criteria as either SCC (n¼ 8) or AC (n¼ 7). Positive
immunohistochemical staining was detected for at least one AKR
in all SCC samples and for two or three AKRs in seven of eight
samples (scoring provided in Table 1, representative images shown
in Supplementary Figure 4). Staining was observed for all three
AKRs in two of seven AC, while no staining was detected in the
remaining five. The difference between SCC and AC was found
to be statistically significant (P¼ 0.0002) by two-tailed Fisher’s
exact test.
AKR mRNA is highly enriched in KEAP1/NRF2 mutant AC and
SCC, but also in KEAP1/NRF2 wild-type SCC. Data were
retrieved from TCGA for NSCLC as described in Materials and
Methods. A comparison of samples wild type or mutant for the
NRF2 pathway demonstrated a highly significant enrichment of
mRNA for all four AKR genes in mutant cases, in both AC and
SCC (Figure 4). In each of the AKR1C1 and AKR1C2 plots, we
noted what appeared to be a distinct cluster of mutant AC (16%
and 18% of the total mutant population, respectively) that had low
expression of the transcript, approximately equal to the wild-type
median level. Case IDs for the 10 samples with the lowest level of
expression of each of the four genes under study were compared
(Supplementary Table 4). There was a high degree of similarity
between the lists indicating that if one of the transcripts was
expressed at a low level it was likely that the other three were also
expressed at a low level. These cases contained a variety of the
specified mutational types: segregation to the low-expression
cluster was not dependent on only one type of pathway alteration.
Moreover, when AKR data from SCC were assessed for co-
expressed genes in cBioPortal (www.cbioportal.org), strong
correlations were observed between AKRs, and of AKRs with
other NRF2-regulated genes, such as GPX2, GSR, PGD, G6PD,
GCLM, GCLC, ME1, SRXN1 and NQO1 (Supplementary Table 5).
There was no association of CUL3 mutation status with AKR
mRNA level in either AC or SCC when all samples were considered
(Supplementary Figure 5), although there was a statistically
significant increase in AKR1B10, AKR1C1 and AKR1C2 mRNA
in SCC when cases which were mutant for KEAP1 and/or NRF2
were removed from the wild-type population (Supplementary
Figure 6).
We compared matched tumour/normal samples from 51 cases
of AC and 53 cases of SCC. For AC, all four AKRs showed a wider
range of expression in tumour tissue than in normal tissue
(Figure 5). This spread of values was largely associated with higher
AKR levels in NRF2/KEAP1mutant cases. Overall, the median level
of AKR1C1, AKR1C2 and AKR1C3 was decreased in tumour,
relative to normal tissue but when only mutant cases were
considered, all AKRs were significantly increased. Paired Wilcoxon
ranked test determined P-values of tumour vs normal gene
expression for matched mutant AC samples (n¼ 10) as follows;
AKR1B10: 0.002, AKR1C1: 0.002, AKR1C2: 0.004, AKR1C3: 0.002.
In SCC, all four AKRs were highly significantly enriched in tumour
tissue, compared with normal, irrespective of mutational status,
although mutant cases generally possessed a higher relative level of
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Figure 2. Chemical activators of NRF2 induce AKR mRNA in human cell lines with wild-type KEAP1 and NRF2. Cells were seeded, incubated
under standard conditions for 24 h, then treated with 5 mmol l1 SFN, 0.2mmol l1 TBE-31 or vehicle control. After a further 24 h, cells were lysed,
cDNA synthesised, and RT–PCR carried out for AKR1B10, AKR1C1/2 and AKR1C3. Fold change values for SFN and TBE-31-treated cells were
calculated relative to vehicle control cells. ND: mRNA for AKR1B10 was not detected in H522, A2780 and T47D cells treated with vehicle,
preventing accurate quantification of fold change.
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expression. Median fold enrichments in SCC were as follows:
AKR1B10: 529-fold, AKR1C1: 16-fold, AKR1C2: 50-fold, AKR1C3:
7-fold. This pattern of enrichment in AC and SCC was also seen
with the other NRF2 target genes, GCLC, GCLM and NQO1,
although HMOX1 was downregulated in both tumour types
(Supplementary Figure 7).
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Figure 3. Constitutive and inducible expression of AKR proteins in human cell lines. (A) Chemical activators of NRF2 induce AKR protein in
human cells possessing wild-type KEAP1/NRF2. Cells were seeded and incubated under standard conditions for 24 h. Medium was replaced
with fresh complete medium containing inducer compounds in acetonitrile (final concentration of acetonitrile, 0.1% (v/v)), then incubated for a
further 24 h. Protein samples were prepared from whole-cell lysates and immunoblotted for AKR1B, AKR1C1/2, AKR1C3 and NQO1. In each
blot, lane 1 contains acetonitrile vehicle control, lane 2 contains 5 mmol l 1 SFN and lane 3 contains 0.2 mmol l 1 TBE-31. Data are
representative of two separate experiments. *NRF2 and KEAP1mutational status in AD293 and HaCaT cell lines unknown. (B–E) Knockdown of
NRF2 leads to decreased AKR1C1/2 expression in A549 and H838 cells. TaqMan RT–PCR was carried out for NRF2 (white bars) and AKR1C1
(black bars) in A549 cells (B) and H838 cells (C) 48 h after mock reverse transfection (transfection reagent alone), or reverse transfection with
siRNA. RTU, relative transcription units. (D) Western blots were carried out for NRF2 (black arrow) and AKR1C1 in A549 cells 120 h after reverse
transfection. Lactate dehydrogenase (LDH) and TATA binding protein (TBP) blots are shown to demonstrate effective separation of the
cytoplasmic and nuclear fractions, respectively. (E) In-Cell ELISA of AKR1C1 was carried out 120 h after reverse transfection in A549 (white
bars) and H838 (black bars) cells. HRP (horseradish peroxidase) signal was adjusted for cell density using Janus Green cell stain. For B, C and E,
statistical significance was calculated relative to mock-transfected control cells. *Pp0.05, **Pp0.01, ***Pp0.001.
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The association of AKR1B10 mRNA expression with tumour
type was investigated in separate microarray data sets using the
Oncomine platform (www.oncomine.org). We found a highly
significant association of AKR1B10 overexpression with SCC of the
lung in multiple analyses; examples from Lee et al (2008) and Zhu
et al (2010) are presented in Supplementary Figure 8. As with
TCGA data, expression of AKR1B10 correlated with that of
AKR1C1, AKR1C2, AKR1C3 and other targets of NRF2, such as
GPX2, GSR, PGD and G6PD, with widespread co-induction in SCC
(examples from Lee et al (2008) and Zhu et al (2010) are shown in
Supplementary Figure 9).
DISCUSSION
The NRF2 pathway may become activated in tumours through a
large number of mechanisms. Core components of the pathway
itself are some of the most frequently mutated genes in cancer, with
mutations in NRF2 and KEAP1 occurring in diverse tumour types
(Singh et al, 2006; Shibata et al, 2008a, b; Kim et al, 2010; Zhang
et al, 2010; Yoo et al, 2012). NRF2 may be transcriptionally
upregulated by oncogenic forms of K-Ras, B-Raf and Myc
(Denicola et al, 2011), although it should be noted here that we
did not find a correlation between mutation in these genes and
enrichment for AKR transcripts (cBioPortal, data not shown).
Alternatively, NRF2 activity may increase in response to stimuli of
exogenous origin, such as chemotherapeutic drugs (McMahon
et al, 2014) or dietary compounds. KEAP1 levels may be decreased
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Figure 4. AKRmRNA is upregulated in both KEAP1/NRF2mutant AC and SCC. TCGA data for NSCLC were processed and analysed as described
in Materials and Methods. Both AC and SCC cases were defined as mutant (MUT) if they possessed one or more of the following: somatic mutation
of KEAP1, loss of heterozygosity of KEAP1, somatic mutation of NRF2, gene amplification of NRF2.
Table 1. Immunohistochemical scoring for NSCLC biopsies
Case AKR1B AKR1C1/2 AKR1C3
AC_1 þ þ þ þ þ þ /
AC_2   
AC_3   
AC_4   
AC_5   
AC_6   
AC_7 þ / þ þ
SCC_1 þ þ þ þ þ þ
SCC_2 þ  þ þ
SCC_3 þ þ þ þ þ þ /
SCC_4 þ þ þ þ þ þ /
SCC_5 þ þ þ 
SCC_6 þ / þ þ 
SCC_7  þ 
SCC_8 þ þ þ þ þ 
Abbreviations: AC¼ adenocarcinoma; SCC¼ squamous cell carcinoma. Intensity of IHC
staining was scored in seven AC and eight SCC biopsies.  , none detected; þ / , trace;
þ , weak; þ þ , moderate, þ þ þ , strong.
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through promoter methylation (Martinez et al, 2013) or by
microRNA-mediated interference (van Jaarsveld et al, 2013), or the
protein itself may be chemically inactivated (Ooi et al, 2011).
Mutation or deletion of CUL3, or methylation of its promoter,
have been reported to occur at high frequencies in certain cancers
(CGARN, 2012; Martinez et al, 2013). While CUL3 is undoubtedly
a key regulator of NRF2 status, its interaction with a large number
of substrate adaptor proteins facilitates the ubiquitination of many
targets. Indeed, mutation of CUL3 did not correlate with increased
expression of NRF2 target genes in the TCGA data sets, and
actually tended towards co-occurrence with mutations in KEAP1
and NRF2 in SCC (cBioPortal, data not shown). We therefore
disregarded this factor in our analyses to maximise specificity for
the NRF2 pathway.
The implication of these (and other) observations is that
constitutive NRF2 activity is far more common in tumours than
has been predicted by the frequency of genomic or epigenomic
alteration of the pathway, and that these analyses cannot therefore
definitively predict its phenotypic status. In order to effectively
interrogate CUL3/KEAP1/NRF2 pathway status, a robust down-
stream signature of activity is required. We had previously
identified AKRs 1B10, 1C1, 1C2 and 1C3 as some of the most
inducible targets of the human NRF2 pathway in the
spontaneously immortalised keratinocyte cell line, HaCaT
(MacLeod et al, 2009), a finding since replicated in non-
tumorigenic MCF10A and MCF12A breast epithelial cells,
virally-immortalised HK-2 kidney cells and the U937 lymphoma
cell line (Agyeman et al, 2012; Jung et al, 2013). Our aim in the
present study was to determine the extent of this relationship
across a large panel of cell lines and tumour samples.
We found that, generally, cultured cell lines are either
responsive to inducers of NRF2, or have mutations in the pathway.
In 23 cell lines of diverse origin we observed high constitutive levels
of expression of AKR1B, AKR1C1/2 and AKR1C3 in three (A549,
H460, HO1-u-1) of seven lines carrying mutant KEAP1 or NRF2.
Further, two (H838, LK-2) of the remaining mutant lines exhibited
high levels of one these enzymes individually. High levels of AKR
coincided with high levels of NRF2. With very few exceptions
(AKR1B in H1395 and H1993, and AKR1C3 in 5637 and
MBA231), AKRs were expressed at relatively low constitutive
levels in cell lines with non-mutated KEAP1/NRF2. Importantly,
the true (relative) level of NRF2 activity in each of these cell lines is
unknown. It has been shown, however, that certain KEAP1
mutations have little or no influence on the capacity of KEAP1 to
repress NRF2 (Hast et al, 2014), which may explain why the H838
and H23 cell lines can carry mutant KEAP1 but express relatively
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Figure 5. Induction of AKR mRNA is more widespread in SCC than in AC, irrespective of KEAP1/NRF2 mutation status. Paired normal/tumour
sample data from TCGA were processed and analysed as described in Materials and Methods. Cases in which the tumour was either wild type
(open circles) or mutant (closed circles) in respect to KEAP1/NRF2 mutation status are shown. Statistical significance of AKR enrichment relative to
normal tissue is calculated as a combined score for both wild-type and mutant cases.
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low (compared with A549, H460 and HO-1-u-1) basal levels of
AKR. In the case of H838, it has previously been shown that these
cells exhibit lower levels of enzymatic activity of NQO1, the most
commonly used proxy for NRF2, than do A549 and H460 (Singh
et al, 2006). In the case of H23, these cells apparently retain the
capacity for NRF2-mediated induction of AKRs, implying that the
KEAP1/NRF2 axis is functional. Regarding the NRF2-mutant cell
lines, and in agreement with our data, Shibata et al (2008b)
reported that NRF2-driven luciferase activity in EBC1 cells was
more responsive than that in LK2 cells to ectopic expression of
KEAP1, suggesting that, as with KEAP1, mutations in NRF2 are
not functionally equivalent. In our analysis of TCGA data, we
observed a strong association of NRF2 pathway mutational status
with AKR mRNA levels, in agreement with the observations of
Cescon et al (2015). Interestingly, we observed a subgroup of
KEAP1/NRF2 mutant AC that did not show enrichment for AKR
mRNA. Conversely, we found that many cases of SCC in which
KEAP1 and NRF2 were wild type exhibited higher levels of AKR
expression than their matched normal controls. Importantly, these
observations suggest that mutation in the KEAP1/NRF2 pathway
and high levels of target gene expression are not interchangeable
descriptors, and that a biomarker signature, such as that described
here, provides a more definitive measure of NRF2 activation
relative to a proxy measure such as genotype/epigenotype.
Furthermore, the assessment of AKR levels potentially constitutes
a means to discriminate between the relative functionality of
KEAP1 and NRF2 mutations and, ultimately, whether they are
likely to influence tumour phenotype.
As Phase I drug metabolism enzymes, AKRs have been
implicated in the bioactivation and detoxification of chemother-
apeutic drugs (Jin and Penning, 2007). Upregulation of AKR
expression by NRF2 could therefore alter chemoresponse, with a
potentially deleterious change in efficacy and/or toxicity. Over-
expression of AKR1Cs has been identified as a mechanism of
resistance to several commonly used agents, for example platinum
compounds (Deng et al, 2004). AKRs have also been implicated in
the genesis of cancer. Two distinct pro-proliferative functions have
been identified for AKR1B10. First, this enzyme converts retinal to
retinol, thereby preventing the generation of retinoic acid and
consequently alleviating the anti-proliferative effect of this
metabolite (Tang and Gudas, 2011). Second, AKR1B10 reduces
farnesal and geranylgeranyl (Endo et al, 2009), a key step in
the process of protein prenylation which is required by KRAS
(and other oncoproteins) for their function. Consistent with this
latter role, chemical inhibition of AKR1B10 was shown to inhibit
carcinogenesis in a KrasG12D/Trp53R172H mouse model of pan-
creatic cancer, with an accompanying decrease in Ras signalling
(Li et al, 2013). Moreover, this function may also, at least in part,
explain why knockout of Nrf2 inhibits the genesis and proliferation
of pancreatic and lung KrasG12D tumours (Denicola et al, 2011). Of
particular relevance to smokers, AKR enzymes metabolically
activate polycyclic aromatic hydrocarbons, converting them to
electrophilic and redox-active o-quinones (Palackal et al, 2002).
These same enzymes are upregulated in response to cigarette
smoke, indicating a further potential mechanistic contribution of
NRF2 dysregulation to tumour genesis and promotion in this
demographic (Zhang et al, 2008). Finally, and possibly relating to
the hormonal metabolism functions of enzymes of the AKR1C
subfamily, the enzymatic activity of ectopically expressed AKR1C1
and AKR1C2 has been shown to enhance tumourigenesis of
NIH3T3 xenografts in mice (Chien et al, 2009). Collectively, these
findings implicate AKRs in the genesis of cancer, extending their
involvement beyond pathways of xenobiotic metabolism. This
potential role is further evidenced by our demonstration of the
ubiquitous nature of the NRF2/AKR relationship.
Upon challenge with chemical inducers of NRF2, we observed
an increase in mRNA for AKR1B10, AKR1C1/2 and AKR1C3 in
almost all cell lines containing non-mutated KEAP1 and NRF2,
whereas cell lines carrying heterozygous mutations in these genes
were less responsive to these compounds and, with the exception of
H23, homozygous mutant cell lines were completely non-
responsive. These findings strongly support the contention that
AKRs are co-regulated as part of the NRF2 gene battery and,
moreover, indicate their potential utility for inferring NRF2
hyperactivation in tumour tissue, irrespective of its mechanistic
origin. Interestingly, AKRs were more markedly induced than
NQO1 following chemical activation of NRF2 in wild-type cells,
which is significant because NQO1 is currently the most widely
used biomarker of NRF2 activation. This contrasts somewhat with
the TCGA analysis, in which NQO1 performed similarly to AKRs.
(Notably, HMOX1, another commonly used proxy for NRF2 levels,
did not show any indication of differential expression in tumours,
mutant or otherwise.) As all NRF2 target genes will be subject to
multifactorial regulation, we suggest that the expression of AKRs
should be considered a signature of NRF2 activity. This signature,
while generally segregating with NRF2/KEAP1 genotype in
cultured cells (i.e., higher expression in mutant cells), did not
appear to do so in lung SCC, as high levels of AKR were detected in
tumours without these mutations. This finding suggests that
additional mechanisms of pathway regulation, potentially those
with roots in the environmental or stromal context of the tumour,
may often be key determinants of its status in vivo. In addition, our
data support the contention that, while the transient activation of
this pathway may be chemopreventive in normal cells, its chronic
activation in cancer cells confers a selective advantage through
enhanced proliferation and chemoresistance.
Non-small cell lung cancer is the tumour type in which KEAP1/
NRF2 dysfunction has most frequently been reported. Within
NSCLC, mutations in KEAP1 occur primarily in AC and mutations
in NRF2 occur primarily in SCC (Singh et al, 2006; Shibata et al,
2008b; Hayes and McMahon, 2009; Kim et al, 2010). More
generally, NRF2 mutations are associated with squamous carcino-
mas irrespective of the tissue of origin. In one study of 1145
carcinoma samples from 13 tissue types, of which 167 were
squamous, 21 of the 22 detected mutations in NRF2 were in SCC
(Kim et al, 2010). In a separate integrative genomic and
epigenomic analysis of SCC of the lung, somatic alteration of the
CUL3/KEAP1/NRF2 pathway was detected in 34% of 178 cases
(CGARN, 2012). Pertinently, most reports of AKR overexpression
in cancer have involved NSCLC. Increased expression of AKR1B
and AKR1C isoforms has been demonstrated to occur in both SCC
and AC of the lung, but in agreement with our analyses these
events are more common in the former subtype (Fukumoto et al,
2005; Inamura et al, 2005; Woenckhaus et al, 2006). Furthermore,
our results are consistent with microarray measurements of
AKR1B10 mRNA transcript levels in SCC and AC of the lung
(Lee et al, 2008; Zhu et al, 2010). As AKR1B10 has been shown to
be highly upregulated in other types of cancer (Balendiran et al,
2009), it would be interesting to determine whether, as with
mutation of NRF2, increased AKR levels segregate to SCC of
tissues other than lung. Future work could also incorporate other
AKRs that are known to be regulated by NRF2 but have not been
included in this study, such as AKR7A2 (Li et al, 2015).
The present work demonstrates that AKR1B10, AKR1C1,
AKR1C2 and AKR1C3 are transcriptional targets strongly indica-
tive of NRF2 status in human tumours, and that NRF2 is the
upstream effector of AKR overexpression in cancer, particularly in
tumours of squamous origin. Although a large number of studies
have identified genetic, epigenetic, signalling and other changes
that can lead to NRF2 hyperactivation in both AC and SCC of the
lung, our data indicate that this is of more widespread downstream
consequence in SCC and, moreover, this hyperactivation fre-
quently occurs in the absence of any somatic mutation of the
pathway. If, as is widely thought, activation of NRF2 supports
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tumour growth and proliferation, targeted inhibition of the NRF2
pathway may constitute a potential therapeutic avenue in most
cases of this cancer type. In conclusion, therefore, the utilisation of
AKRs as biomarkers of NRF2 status will ultimately help determine
the significance of this pathway in cancer genesis and progression,
and of its potential roles in disease management and the design of
therapeutic strategies.
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